Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c

November 9, 2016 7:06 AM EST
Get Alerts ITCI Hot Sheet
Trade ITCI Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities

The Children's Investment Fund (TCI), Earnings

Add Your Comment